Journal Information

Statistics

Follow this link to access the full text of the article

Original article
Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method
Astrid Pavlovskya,b, Juan Ignacio Garcia Altuvec, Amalia Ceruttid, Lorena Fiade, Nicolás Kurganskyf, Fernando Warleyg,
Corresponding author
fernando.warley@hospitalitaliano.org.ar

Corresponding author at: Hematology Section, Internal Medicine Department, Hospital Italiano de Buenos Aires, Tte. Gral. J. D. Perón 4190, Buenos Aires, Argentina.
, Florencia Negri Arangurenh
a Centro de Hematologia Pavlovsky, Buenos Aires, Argentina
b FUNDALEU, Buenos Aires, Argentina
c Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina
d Sanatorio Británico de Rosario, Santa Fé, Argentina
e Hospital Italiano La Plata, Buenos Aires, Argentina
f DOCTUS, Buenos Aires, Argentina
g Hospital Italiano de Bueno Aires, Buenos Aires, Argentina
h Instituto Privado de Hematologia y Hemoterapia, Entre Ríos, Argentina
Read
1071
Times
was read the article
192
Total PDF
879
Total HTML
Share statistics
Article information
ISSN: 25311379
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 April 78 18 96
2025 March 85 11 96
2025 February 80 26 106
2025 January 104 26 130
2024 December 88 20 108
2024 November 136 41 177
2024 October 284 38 322
2024 September 24 12 36

Follow this link to access the full text of the article

Idiomas
Hematology, Transfusion and Cell Therapy